关注
Bruno Sangro
Bruno Sangro
Professor of Medicine, Universidad de Navarra
在 unav.es 的电子邮件经过验证
标题
引用次数
引用次数
年份
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...
The Lancet 389 (10088), 2492-2502, 2017
40112017
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade
PJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ...
Journal of Clinical Oncology 33 (6), 550, 2015
22492015
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ...
Journal of hepatology 76 (3), 681-693, 2022
20872022
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
M Reig, Z Mariño, C Perelló, M Iñarrairaegui, A Ribeiro, S Lens, A Díaz, ...
Journal of hepatology 65 (4), 719-726, 2016
10392016
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
B Sangro, C Gomez-Martin, M de la Mata, M Iñarrairaegui, E Garralda, ...
Journal of hepatology 59 (1), 81-88, 2013
10382013
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial
T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ...
JAMA oncology 6 (11), e204564-e204564, 2020
9542020
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ...
Annals of oncology 29, iv238-iv255, 2018
8962018
Advances in immunotherapy for hepatocellular carcinoma
B Sangro, P Sarobe, S Hervás-Stubbs, I Melero
Nature reviews Gastroenterology & hepatology 18 (8), 525-543, 2021
8032021
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular …
T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ...
Annals of Oncology 30, v874-v875, 2019
7442019
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions
L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ...
Seminars in liver disease 32 (04), 348-359, 2012
7242012
Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
B Sangro, L Carpanese, R Cianni, R Golfieri, D Gasparini, S Ezziddin, ...
Hepatology 54 (3), 868-878, 2011
7042011
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ...
The Lancet Oncology 23 (1), 77-90, 2022
7022022
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors
B Sangro, G Mazzolini, J Ruiz, M Herraiz, J Quiroga, I Herrero, A Benito, ...
Journal of clinical oncology 22 (8), 1389-1397, 2004
7002004
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization
JL Raoul, B Sangro, A Forner, V Mazzaferro, F Piscaglia, L Bolondi, ...
Cancer treatment reviews 37 (3), 212-220, 2011
6602011
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ...
NEJM evidence 1 (8), EVIDoa2100070, 2022
5842022
Immunological landscape and immunotherapy of hepatocellular carcinoma
J Prieto, I Melero, B Sangro
Nature reviews Gastroenterology & hepatology 12 (12), 681-700, 2015
5582015
New therapies for hepatocellular carcinoma
MA Avila, C Berasain, B Sangro, J Prieto
Oncogene 25 (27), 3866-3884, 2006
5162006
Liver disease induced by radioembolization of liver tumors: description and possible risk factors
B Sangro, B Gil‐Alzugaray, J Rodriguez, I Sola, A Martinez‐Cuesta, ...
Cancer 112 (7), 1538-1546, 2008
4092008
Radioembolization for hepatocellular carcinoma
B Sangro, M Iñarrairaegui, JI Bilbao
Journal of hepatology 56 (2), 464-473, 2012
3752012
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
TH Karlsen, N Sheron, S Zelber-Sagi, P Carrieri, G Dusheiko, E Bugianesi, ...
The Lancet 399 (10319), 61-116, 2022
3482022
系统目前无法执行此操作,请稍后再试。
文章 1–20